Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

NCT ID: NCT00445068

Last Updated: 2021-07-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-16
• Study Completion Date: 2009-12-25

Brief Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide

Conditions

Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Panobinostat

Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

LBH589

Intervention Type: DRUG

Interventions

LBH589

Intervention Type: DRUG

Other Intervention Names

Panobinostat

Eligibility Criteria

Inclusion Criteria

1. Adults ≥ 18 years old

2. Subjects must have signed the consent form before undergoing any study specific screening procedures and before participation in this study. The subject must be fully informed by the investigator of the nature and potential risks of participation in this study.

3. Patients must have had a diagnosis of symptomatic multiple myeloma (from IMWG see (Kyle et al,2003) meeting all three of the following criteria:

• Monoclonal immunoglobulin (spike on electrophoresis, or band on immunofixation) on serum or on 24 hour urine.
• Bone marrow (clonal) plasma cells or plasmacytoma

Exclusion Criteria

4. Subjects must have received at least two prior lines of therapy and be refractory to the most recent line of therapy according to the following definitions: Refractory to most recent line of therapy Defined by disease progression during treatment or within 60 - 100 days after the completion of the most recent line of therapy. This includes the development of disease progression during maintenance or consolidation therapy with high dose glucocorticoids, or any other specific MM therapy Sixty days is counted from the point in time when the first response assessment is performed after completion of the last line of therapy. At a maximum, disease progression should be documented within 100 days after the last day of the last dose of any anti-MM therapy, including if last regimen of the most recent line of therapy was Autologous Stem Cell Transplant (ASCT). Stable disease patients also part of the IMWG definition are not eligible for this trial. At study screening, Progressive Disease (PD) will be assessed by comparing screening values or symptoms in reference to the baseline (values or symptoms) of their last line of therapy. Should a patient have experienced an initial response on their last line of therapy, PD should be assessed in reference to the lowest values of the initial confirmed response Minimal Response(MR) / Partial Response (PR) / Complete Response (CR).

Disease progression is defined by having one or more of the following:

• >25% increase in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation.
• >25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation.
• >25% increase in plasma cells in a bone marrow aspirate or on bone marrow biopsy, which must also be an absolute increase of at least 10%
• Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.
• Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).

5. Subjects must have previously been treated with bortezomib and at least one of the following: lenalidomide or thalidomide

6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

7. Patients must have the following hematological laboratory values:

• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (or ≥1.0 x 109/L if the neutropenia is clinically related to progressive myeloma with bone marrow infiltration of > 50% involvement
• Hemoglobin ≥ 8.0 g/dl
• Platelets ≥ 75.0 x 109/L (or ≥ 50.0 x 109/L x if the thrombocytopenia is clinically related to progressive myeloma with bone marrow infiltration > 50% involvement

8. Patients must have the following renal function as shown by :

• Calculated Creatinine Clearance (CrCL) > 30ml/min (Cockcroft and Gault formula)

9. Patients must have adequate liver function as shown by:

• Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 x Upper limit of normal (ULN)
• Serum bilirubin ≤ 1.5 x ULN
• Albumin ≥ 2.5 g/dl

10. Patients must have the following non-hematological laboratory values:

• Serum potassium ≥ Lower Limit of Normal (LLN),
• Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN,
• Serum magnesium ≥ LLN
• Serum phosphorus ≥ LLN
• Normal thyroid function (TSH and free T4) (hypothyroidism correctable with supplements is allowed)

11. Baseline Multiple Uptake Gated Acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate Left Ventricular Ejection Fraction (LVEF) ≥ the lower limit of the institutional normal

12. Patients must be willing and able to undergo bone marrow aspirates as per protocol, with/without bone marrow biopsy according to their center's practice. The bone marrow aspirate /biopsy must be adequate to allow for comparison for the later efficacy response assessments.

13. Patients must have an M component at baseline above a minimum threshold of: 1g/dl (10g/L) for serum M component, or 200mg/24h urine M component.

1. Prior therapy with an Histone Deacetylase (HDAC) inhibitor for the treatment of Multiple Myeloma (MM)

2. Patients with non-secretory MM

3. Patients who have received allogenic stem cell transplantation < 12 months prior to study

4. Patients who have had prior allogenic stem cell transplantation and show evidence of active graft versus-host disease that requires immunosuppressive therapy

5. Patients with amyloidosis

6. Patients with peripheral neuropathy > grade 2

7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

• Patients with congenital long QT syndrome
• History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment)
• Any history of ventricular fibrillation or torsade de pointes
• Bradycardia defined as Heart Rate (HR)< 50 bpm. Patients with pacemakers are eligible if HR ≥ 50 bpm.
• Screening Electrocardiogram (ECG) with a corrected QT interval (QTc) > 450 msec
• Right bundle branch block + left anterior hemi-block (bi-fascicular block)
• Patients with myocardial infarction or unstable angina ≤ 6 months prior to starting study drug

8. Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF NY) Heart Association class III or IV, uncontrolled hypertension, or history of poor compliance with an antihypertensive regimen)

9. Impairment of GI function or GI disease that may significantly alter the absorption of LBH589

10. Patients with unresolved diarrhea > CTCAE grade 1.

11. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol

12. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsades de pointes if the medications cannot be discontinued or switched to a different medication prior to starting study drug

13. Concomitant use of CYP3A4 inhibitors

14. Patients with an active bleeding diathesis or on any treatment with therapeutic doses of sodium warfarin (Coumadin®) or any other anti-vitamin K drug. Low doses of Coumadin® (e.g., ≤ 2 mg/day), or low doses of any other anti-vitamin K drug, for line patency is allowable

15. Patients who have received chemotherapy, radiation therapy or any investigational drugs, bortezomib or other immunomodulatory therapy (e.g., thalidomide, lenalidomide) or immunotherapy ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy

16. Patients who have received high-dose corticosteroids as the only component of their most recent line of therapy

17. Patients who have received steroids (e.g., dexamethasone) ≤ 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy. Concomitant therapy medications that include corticosteroids are allowed if subjects receive < 20 mg of prednisone or equivalent as indicated for other medical conditions (and not as maintenance or an anticancer therapy for MM), or up to 100 mg of hydrocortisone as premedication for a administration of certain medications or blood products, while enrolled in this study.

18. Patients whose clinical condition would need valproic acid therapy during study or ≤ 5 days prior to starting drug

19. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

20. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)not willing to use a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589

21. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and for 3 months after treatment. One of these methods of contraception must be a condom

22. Patients with a current second malignancy or a prior malignancy within the last 5 years except adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

23. Patients with any significant history of non compliance to medical regimens or unwilling or unable to comply with the protocol or unable to grant reliable informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Mayo Clinic

Scottsdale, Arizona, United States

Aptium Oncology

Berkeley, California, United States

City of Hope

Duarte, California, United States

UCSF

San Francisco, California, United States

Stanford

Stanford, California, United States

Rocky Mountain Cancer Center

Denver, Colorado, United States

Christiana Care

Newark, Delaware, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Rush University

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

University of Iowa

Iowa City, Iowa, United States

Dana Farber

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Washington University

St Louis, Missouri, United States

Hackensack University

Hackensack, New Jersey, United States

Duke

Durham, North Carolina, United States

Wake Forest

Winston-Salem, North Carolina, United States

Metrohealth

Cleveland, Ohio, United States

Sarah Canon Research Center

Nashville, Tennessee, United States

Vanderbilt

Nashville, Tennessee, United States

University of Texas Southwestern

Dallas, Texas, United States

CTRC

San Antonio, Texas, United States

Novartis investigative Site

Berlin, , Germany

Novartis Investigative Site

Heidelberg, , Germany

Novartis Investigative Site

Kiel, , Germany

Novartis Investigative Site

Starnberg, , Germany

Novartis Investigative Site

Würzburg, , Germany

Countries

United States; Germany

Other Identifiers

CLBH589B2203

Identifier Type: -

Identifier Source: org_study_id